- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Do | J&J's Caplyta wins MDD approval to extend revenue horizon | ||
| Do | Former blockbuster Linzess grows label with paediatric IBS-C approval | ||
| Do | Novo Nordisk's oral Wegovy reduces cardiovascular risk factors in obesity | ||
| Do | Cencora to invest $1bn in US pharma distribution network | ||
| Do | Leukogene Therapeutics gains FDA ODD status for M2T-CD33 | ||
| Mi | Novo Nordisk latest outlook trim shows "quick momentum loss" | ||
| Mi | Agentic, deeply embedded AI constitutes the "next wave" of tech | ||
| Mi | Avant and SGAustria form JV to develop diabetes therapy | ||
| Mi | Novo Nordisk and Pfizer's bidding war for Metsera escalates despite legal threats | ||
| Mi | MSD secures $700m for broad-cancer ADC asset | ||
| Mi | AmacaThera and Pacira sign agreement for AMT-143 | ||
| Mi | Boehringer and CDR-Life announce licensing deal for autoimmune disease therapy | ||
| Di | FDA halts uniQure's plans for Huntington's disease gene therapy | ||
| Di | Tidmarsh's FDA exit marks latest high-profile jockeying at US agencies | ||
| Di | Kimberly-Clark buys troubled Tylenol-maker Kenvue for $48.7bn | ||
| Di | FDA approves UCB's Kygevvi for genetic mitochondrial disease | ||
| Di | Eli Lilly to invest $3bn in new Dutch manufacturing facility | ||
| Di | Alvotech faces FDA setback for its Simponi biosimilar AVT05 | ||
| Mo | Pfizer hits Novo Nordisk and Metsera with lawsuit amid bidding war | ||
| Mo | IntoCell and Xcellon Biologics to advance ADC development | ||
| Mo | 4DMT and Otsuka to advance eye disease treatment in APAC | ||
| 31.10. | Sensei to ditch its lead candidate and cut workforce amidst strategic review | ||
| 31.10. | Massive sales for weight loss drugs spur Eli Lilly's Q3 | ||
| 31.10. | Debiopharm and NetTargets to identify synergistic drug combos for ADCs | ||
| 31.10. | Helex secures $3.5m to advance kidney disease therapies |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .